

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined in this announcement, capitalised terms used herein shall have the same meanings as those defined in the prospectus dated Wednesday, December 18, 2024 (the “**Prospectus**”) issued by Xunfei Healthcare Technology Co., Ltd. (訊飛醫療科技股份有限公司) (the “**Company**”).

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer to sell or solicitation of an offer to buy, to purchase or subscribe for securities nor shall there be any sale of Offer Shares in the United States or in any other jurisdictions in which such offer or solicitation would be unlawful.

The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States. The securities may not be offered, sold, pledged, or transferred within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act (“**Regulation S**”)) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offering of securities in the United States. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

In connection with the Global Offering, Huatai Financial Holdings (Hong Kong) Limited, as stabilising manager (the “**Stabilising Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may effect transactions with a view to stabilising or supporting the market price of the H Shares at a level higher than that which might otherwise prevail for a limited period on and after the Listing Date. However, there is no obligation on the Stabilising Manager, its affiliates or any person acting for it, to conduct any such stabilising action, which, if commenced, will be done at the sole and absolute discretion of the Stabilising Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilising action is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering, being Wednesday, January 22, 2025. Such stabilisation action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Cap. 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Potential investors of the Offer Shares should note that the Joint Sponsors and the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8: 00 a.m. (Hong Kong time) on the Listing Date.

# XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.

## 訊飛醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

### GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 7,035,550 H Shares
Number of Hong Kong Offer Shares	: 703,600 H Shares
Number of International Offer Shares	: 6,331,950 H Shares
Offer Price	: HK\$82.8 per H Share plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund)
Nominal value	: RMB1.00 per H Share
Stock Code	: 2506

#### Joint Sponsors, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers



#### Joint Bookrunners and Joint Lead Managers



#### Joint Lead Manager



**Xunfei Healthcare Technology Co., Ltd.**  
**訊飛醫療科技股份有限公司**  
**ANNOUNCEMENT OF ALLOTMENT RESULTS**

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated 18 December 2024 (the “Prospectus”) issued by Xunfei Healthcare Technology Co., Ltd. (the “Company”).

**Warning: In view of high concentration of shareholding in a small number of H Shareholders, H Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.**

**SUMMARY**

**Company information**

<b>Stock code</b>	2506
<b>Stock short name</b>	XUNFEIHEALTH
<b>Dealings commencement date</b>	30 December 2024*

\*see note at the end of the announcement

**Price Information**

<b>Final Offer Price</b>	HK\$82.800
<b>Offer Price Range</b>	N/A
<b>Offer Price Adjustment exercised</b>	No

**Offer Shares and Share Capital**

<b>Number of Offer Shares</b>	7,035,550
<b>Number of Offer Shares in Public Offer</b>	703,600
<b>Number of offer shares in International Offer</b>	6,331,950
<b>Number of issued shares upon Listing</b>	120,878,233

**Over-allocation**

<b>No. of Offer Shares over-allocated</b>	0
---	---

The Overall Coordinators confirmed that there has been no over-allocation of the Offer Shares in the International Offering. Therefore, it is expected that the Over-Allotment Option will not be exercised.

**Proceeds**

<b>Gross proceeds<sup>(Note)</sup></b>	HK\$ 582.54 million
<b>Less: Estimated listing expenses payable based on Final Offer Price</b>	HK\$ (75.40) million
<b>Net proceeds</b>	HK\$ 507.14 million

Note: Gross proceeds refer to the amount which the Company is entitled to receive. For details of the use of proceeds, please refer to the section headed “Future Plans and Use of Proceeds” of the Prospectus.

## ALLOTMENT RESULTS DETAILS

### PUBLIC OFFER

<b>No. of valid applications</b>	3,136
<b>No. of successful applications</b>	2,822
<b>Subscription level</b>	3.66 times
<b>Claw-back triggered</b>	No
<b>No. of Offer Shares initially available under the Public Offer</b>	703,600
<b>Final no. of Offer Shares under the Public Offer</b>	703,600
<b>% of Offer Shares under the Public Offer to the Global Offering</b>	10.00%

Note: For details of the final allocation of shares to the Public Offer, investors can refer to <https://www.hkeipo.hk/iporesult> to perform a search by name or identification number or <https://www.hkeipo.hk/iporesult> for the full list of allottees.

### INTERNATIONAL OFFER

<b>No. of places</b>	116
<b>Subscription Level</b>	1.10 times
<b>No. of Offer Shares initially available under the International Offer</b>	6,331,950
<b>Final no. of Offer Shares under the International Offer</b>	6,331,950
<b>% of Offer Shares under the International Offer to the Global Offering</b>	90.00%

The Directors confirm that, to the best of their knowledge, information and belief, save for a waiver from strict compliance with Rule 10.04 of the Listing Rules and a consent under paragraph 5(2) of Appendix F1 to the Listing Rules (the “**Placing Guidelines**”) granted by the Stock Exchange to permit the Company to allocate certain Offer Shares in the International Offering to a close associate of the existing shareholder as cornerstone investor, (i) none of the Offer Shares subscribed by the places and the public have been financed directly or indirectly by the Company, any of the Directors, Supervisors, chief executive of the Company, substantial Shareholders, existing Shareholders or any of its subsidiaries or their respective close associates; and (ii) none of the places and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, Supervisors, chief executive of the Company, substantial Shareholders, existing Shareholders or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of H Shares registered in his/her/its name or otherwise held by him/her/it.

The places in the International Offer include the following:

#### Cornerstone Investors

<b>Investor</b>	<b>No. of Offer Shares allocated</b>	<b>% of Offer Shares</b>	<b>% of total issued H Shares after the Global Offering</b>	<b>% of total issued share capital after the Global Offering</b>	<b>Existing shareholders or their close associates</b>
Guangdong-Macao In-Depth Cooperation Zone in Hengqin	751,700	10.68%	0.97%	0.62%	No

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares</i>	<i>% of total issued H Shares after the Global Offering</i>	<i>% of total issued share capital after the Global Offering</i>	<i>Existing shareholders or their close associates</i>
Industrial Investment Fund (Limited Partnership)					
Star Group Limited	338,150	4.81%	0.44%	0.28%	Yes <sup>(Note)</sup>
Costone China Growth Capital I L.P.	751,700	10.68%	0.97%	0.62%	No
Xunyi Limited	748,750	10.64%	0.97%	0.62%	No
Honour Goal Investments Limited	751,700	10.68%	0.97%	0.62%	No
<b>Total</b>	<b>3,342,000</b>	<b>47.50%</b>	<b>4.32%</b>	<b>2.76%</b>	

*Note: Star Group Limited is wholly owned by China Merchants China Direct Investments Limited whose shares have been listed on the Stock Exchange of Hong Kong (Stock Code: 00133), and is a close associate of our existing Shareholder, namely, Tianzheng Investment. For further details of the Cornerstone Investors, please refer to the section headed "Cornerstone Investors" of the Prospectus.*

***Allottees with waivers/consents obtained***

<i>Investor</i>	<i>No. of shares allocated</i>	<i>% of offer shares</i>	<i>% of total issued H Shares after the Global Offering</i>	<i>% of total issued share capital after the Global Offering</i>	<i>Relationship*</i>
Guangdong-Macao In-Depth Cooperation Zone in Hengqin Industrial Investment Fund (Limited Partnership)	751,700	10.68%	0.97%	0.62%	A connected client of GF Securities Brokerage (Hong Kong) Limited, the Overall Coordinator <sup>(Note)</sup>
Star Group Limited	338,150	4.81%	0.44%	0.28%	A close associate of Tianzheng Investment, an existing Shareholder <sup>(Note)</sup>
<b>Total</b>	<b>1,089,850</b>	<b>15.49%</b>	<b>1.41%</b>	<b>0.90%</b>	

*Note: Please refer to the section headed "Waivers from Strict Compliance with the Listing Rules" of the Prospectus for details of the waiver and consents obtained*

## LOCK-UP UNDERTAKINGS

### Controlling Shareholders

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H-shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings (Note)</i>
iFlytek Co., Ltd.	59,738,145 Shares (including 29,869,073 H Shares)	38.64%	49.42%	December 29, 2025
<b>Subtotal</b>	<b>59,738,145</b>	<b>77.28%</b>	<b>49.42%</b>	

*Note: According to the PRC Company Law, all the Shares held by the existing Shareholders (including the Controlling Shareholder) prior to the Global Offering are subject to a lock-up period of one year from the Listing Date.*

### Cornerstone Investors

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings (Note)</i>
Star Group Limited	338,150	0.44%	0.28%	June 29, 2025
Honour Goal Investments Limited	751,700	0.97%	0.62%	June 29, 2025
Guangdong-Macao In-Depth Cooperation Zone in Hengqin Industrial Investment Fund (Limited Partnership)	751,700	0.97%	0.62%	June 29, 2025
Xunyi Limited	748,750	0.97%	0.62%	June 29, 2025
Costone China Growth Capital I L.P.	751,700	0.97%	0.62%	June 29, 2025
<b>Subtotal</b>	<b>3,342,000</b>	<b>4.32%</b>	<b>2.76%</b>	

*Note: In accordance with the Cornerstone Investment Agreement, the required lock-up ends on June 29, 2025. The Cornerstone Investors will cease to be prohibited from disposing of or transferring H Shares subscribed for pursuant to their respective Cornerstone Investment Agreement after the indicated date.*

### Existing Shareholders

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings (Note)</i>
Hefei Zhengsheng Information Technology Partnership (Limited Partnership)	19,473,294 Shares (including 9,736,647 H Shares)	12.60%	16.11%	December 29, 2025
Anhui Kexun Venture Capital Fund Partnership (Limited Partnership)	17,448,567 H Shares	22.57%	14.43%	December 29, 2025
Mr. Hu Guoping	4,479,871 H Shares	5.80%	3.71%	December 29, 2025
<b>Subtotal</b>	<b>41,401,732 Shares (including 31,665,085 H Shares)</b>	<b>40.97%</b>	<b>34.25%</b>	

*Note 1: According to the PRC Company Law, all the Shares held by existing Shareholders prior to the Global Offering are subject to a lock-up period of one year from the Listing Date.*

### Pre-IPO Investors (as defined in the section headed “History, Development and Corporate Structure — Pre-IPO Investments” in the Prospectus)

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon listing</i>	<i>Last day subject to the lock-up undertakings (Note 1)</i>
Pre-IPO Investors <sup>(Note 2)</sup>	12,702,806 Shares (including 8,727,404 H Shares)	11.29%	10.51%	December 29, 2025

Notes:

- (1) According to the PRC Company Law, all the Shares held by existing Shareholders (including the Pre-IPO Investors) prior to the Global Offering are subject to a lock-up period of one year from the Listing Date.
- (2) Please refer to the section headed “History, Development and Corporate Structure — Pre-IPO Investments” in the Prospectus for details.

***PLACEE CONCENTRATION ANALYSIS***

<b>Placees</b> <i>(Note 1)</i>	<b>Number of H Shares allotted</b>	<b>Allotment as % of International Offering</b>	<b>Allotment as % of total Offer Shares</b>	<b>Number of Shares held upon Listing</b>	<b>% of total issued share capital upon Listing</b>
Top 1	751,700	11.87%	10.68%	751,700	0.62%
Top 5	3,755,550	59.31%	53.38%	3,755,550	3.11%
Top 10	5,991,250	94.62%	85.16%	9,891,250	8.18%
Top 25	6,327,400	99.93%	89.93%	10,227,400	8.46%

*Notes:*

- 1. Ranking of placees is based on the number of H Shares allotted to the placees*



***H SHAREHOLDERS CONCENTRATION ANALYSIS***

<b>H Shareholders</b> <i>(Note 1)</i>	<b>Number of H Shares allotted</b>	<b>Number of H Shares allotted under International Offering</b>	<b>Allotment as % of International Offering</b>	<b>Allotment as % of total Offer Shares</b>	<b>Number of H Shares held upon Listing</b>	<b>% of total issued H Shares capital upon Listing</b>
Top 1	0	0	0.00%	0.00%	29,869,073	38.64%
Top 5	338,150	338,150	5.34%	4.81%	66,398,833	85.90%
Top 10	3,344,950	3,344,950	52.83%	47.54%	70,155,633	90.76%
Top 25	6,414,500	6,235,450	98.48%	91.17%	76,676,062	99.20%

*Note:*

1. Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.

***SHAREHOLDER CONCENTRATION ANALYSIS***

<b>Shareholders</b> <i>(Note 1)</i>	<b>Number of H Shares allotted</b>	<b>Number of H Shares allotted under International Offering</b>	<b>Allotment as % of International Offering</b>	<b>Allotment as % of total Offer Shares</b>	<b>Number of H Shares held upon Listing</b>	<b>Number of Shares held upon Listing</b>	<b>% of total issued share capital upon Listing</b>
Top 1	0	0	0.00%	0.00%	29,869,073	59,738,145	49.42%
Top 5	338,150	338,150	5.34%	4.81%	66,398,833	106,631,076	88.21%
Top 10	1,089,850	1,089,850	17.21%	15.49%	69,648,363	113,026,435	93.50%
Top 25	6,414,500	6,235,450	98.48%	91.17%	76,676,062	120,257,183	99.49%

*Note:*

1. Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.

***BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING***

Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by the public will be conditionally allocated on the basis set out below:

<b>NO. OF H SHARES APPLIED FOR</b>	<b>NO. OF VALID APPLICATIONS</b>	<b>BASIS OF ALLOTMENT/BALLOT</b>	<b>APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF H SHARES APPLIED FOR</b>
50	314	0 H Shares	80.05%
50	1,260	50 H Shares	
100	449	50 H Shares	53.03%
100	29	100 H Shares	
150	71	50 H Shares	48.03%
150	56	100 H Shares	
200	33	50 H Shares	43.13%
200	87	100 H Shares	
250	112	100 H Shares	40.00%
300	42	100 H Shares	
300	12	150 H Shares	37.04%
350	9	100 H Shares	
350	11	150 H Shares	36.43%
400	6	100 H Shares	
400	24	150 H Shares	35.00%
450	12	150 H Shares	
500	140	150 H Shares	33.33%
500	55	200 H Shares	
600	9	150 H Shares	32.82%
600	25	200 H Shares	
700	16	200 H Shares	31.13%
800	9	200 H Shares	
800	9	250 H Shares	28.57%
900	10	250 H Shares	
1,000	119	250 H Shares	28.13%
1,000	18	300 H Shares	
1,500	32	350 H Shares	27.78%
2,000	30	400 H Shares	
2,500	33	450 H Shares	25.66%
3,000	19	500 H Shares	
3,500	6	550 H Shares	23.33%
4,000	8	600 H Shares	
4,500	4	650 H Shares	20.00%
5,000	20	700 H Shares	
6,000	8	800 H Shares	18.00%
7,000	2	900 H Shares	
8,000	1	1,000 H Shares	16.67%
9,000	1	1,100 H Shares	
10,000	15	1,200 H Shares	15.71%
			15.00%
			14.44%
			14.00%
			13.33%
			12.86%
			12.50%
			12.22%
			12.00%

20,000	7	2,200 H Shares	11.00%
30,000	3	3,200 H Shares	10.67%
40,000	1	4,200 H Shares	10.50%
50,000	1	5,200 H Shares	10.40%
70,000	1	22,850 H Shares	32.64%
80,000	1	26,100 H Shares	32.63%
90,000	2	29,350 H Shares	32.61%
100,000	2	32,550 H Shares	32.55%
200,000	1	65,000 H Shares	32.50%
351,800	1	114,050 H Shares	32.42%
Total	3,136	703,600 H Shares	

*As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.*

### **COMPLIANCE WITH LISTING RULES AND GUIDANCE**

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the places or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and trading fee payable.

### **OTHERS / ADDITIONAL INFORMATION**

#### **ALLOCATION OF H SHARES TO A CLOSE ASSOCIATE OF AN EXISTING SHAREHOLDER**

We have applied for, and the Stock Exchange has granted, a waiver from strict compliance with the requirements under Rule 10.04 of, and a consent under paragraph 5(2) of Appendix F1 to, the Listing Rules, to allow Star Group, a close associate of an existing Shareholder, to subscribe for Offer Shares in the Global Offering as a cornerstone investor.

#### **THE PROPOSED SUBSCRIPTION OF H SHARES BY HENGQIN INVESTMENT FUND THROUGH GF SECURITIES ASSET MANAGEMENT(GUANGDONG) CO., LTD.**

We have applied for, and the Stock Exchange has granted, a consent under paragraph 5(1) of Appendix F1 to the Listing Rules to permit Hengqin Investment Fund (through GF Securities AM as the asset manager) to participate in the Global Offering as a cornerstone investor.

The allocation of Offer Shares to such close associate of Tianzheng Investment and such connected client of GF Securities Brokerage (Hong Kong) Limited is in compliance with all the conditions under the waiver/consent granted by the Stock Exchange. For details, please refer to the section headed "Allotment Results Details – International Placing – Allotees with Waivers/Consents Obtained" in this announcement.

## DISCLAIMERS

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.*

*The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated 18 December 2024 issued by Xunfei Healthcare Technology Co., Ltd. for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered.*

*\*Potential investors of the Offer Shares should note that Joint Sponsors and Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Hong Kong Underwriting Agreement – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on 30 December 2024).*

## **PUBLIC FLOAT**

The Stock Exchange has granted the Company a waiver from strict compliance with the minimum public float requirement under Rule 8.08(1)(a) of the Listing Rules so that the minimum public float of the Company will be the higher of (a) 15.67% of the total number of issued Shares and (b) such percentage of H Shares to be held by the public immediately after completion of the Global Offering (the “**Public Float Waiver**”).

Immediately following the completion of the Global Offering, 18,939,470 H Shares, representing approximately 15.67% of the total number of issued Shares, will be held in the public hands, satisfying the minimum percentage as prescribed by the Public Float Waiver.

The Directors confirm that, immediately following the completion of the Global Offering, (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial shareholder (as defined in the Listing Rules) immediately after the Global Offering; (iii) the three largest public shareholders of the Company do not hold more than 50% of the H Shares in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

## **COMMENCEMENT OF DEALINGS**

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Monday, December 30, 2024, provided that the Global Offering has become unconditional and the right of termination described in the paragraph headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk. Assuming that the Global Offering becomes unconditional in all respects at or before 8:00 a.m. on Monday, December 30, 2024, it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Monday, December 30, 2024. The H Shares will be traded in board lots of 50 H Shares each. The stock code of the H Shares is 2506.

By order of the Board  
**Xunfei Healthcare Technology Co., Ltd.**  
**Dr. Tao Xiaodong**  
*Executive Director*

Hong Kong, December 27, 2024

*As of the date this announcement, the board of directors of the Company comprises: (i) Dr. Tao Xiaodong as executive director; (ii) Dr. Liu Qingfeng, Mr. Zhao Zhiwei and Mr. Duan Dawei as non-executive directors; and (iii) Prof. Wang Yang, Prof. Zhao Huifang and Mr. Tan Ching as independent non-executive director.*